Objective: To review the literature for α-blocker treatment of kidney stones. Data Sources: PubMed search performed November 15, 2017, using the following search terms: alpha-blocker, alfuzosin, silodosin, or tamsulosin AND kidney or ureteral stones. Additional studies found through references of primary and tertiary literature. Inclusion criteria included English language, randomized controlled trials (not included in meta-analyses), and meta-analyses evaluating US available alpha-blockers as medical expulsive therapy with or without lithotripsy in adults with renal or ureteral stones, and no date limits. Study Selection and Data Extraction: Seven randomized controlled trials (RCTs), 1 case-control trial, and 6 meta-analyses were found and included in this review. Two RCTs and 4 meta-analyses evaluated alpha-blockers without lithotripsy. Five RCTs, 1 case-control trial, and 2 meta-analyses evaluated their use post-lithotripsy. The primary endpoint was stone clearance rate in most studies. Data Synthesis: For ureteral stones ≤10 mm treated without lithotripsy, alpha-blockers increased clearance in all meta-analyses and one RCT versus control. For ureteral or renal stones treated with lithotripsy, 4 RCTs and all meta-analyses found benefit with alpha-blockers compared with control. When results were stratified by stone size, alpha-blockers performed better for stones 10 to 20 mm, while there was no difference for stones <10 mm. Conclusion: Alpha-blockers are beneficial without lithotripsy for ureteral stones 5 to 10 mm. They are beneficial post-lithotripsy for renal or ureteral stones >10 mm. They can be considered post-lithotripsy for stones 5 to 10 mm, but little benefit may be seen. Although all uroselective alpha-blockers have been found to be effective, most data are with tamsulosin 0.4 mg daily.
Background
Kidney stones are a common and growing problem in the United States. A recent survey found that 11% of men and 7% of women will experience at least one kidney stone in their lifetime. Recurrence is estimated to be ≤50% at 5 years. Risk factors include male gender, obesity, diabetes, gout, and income less than $75 000. Noncontrast computed tomography imaging is typically used to confirm diagnosis and estimate stone size. Pain is the most common symptom and occurs when the stone attempts to pass through the ureter. Kidney stones are often asymptomatic while growing and may take up to several months to grow to a detectable size. [1] [2] [3] Treatment of kidney stones depends on factors such as stone size and symptoms. Waiting for a stone to pass spontaneously is the recommended treatment for stones <5 mm with little to no pain. Management options for larger and painful stones include shockwave lithotripsy (SWL), ureteroscopy, surgical removal, and pharmacologic therapy. While the traditional role of pharmacologic therapy is for symptomatic relief or to prevent recurrence, some studies suggest using medications to promote the passage of stones and shorten the time it takes to pass the stone spontaneously. This is referred to as medical expulsive therapy (MET) and is where the use of alpha-blockers has been studied. MET can be used as monotherapy, post-lithotripsy, or with additional pharmacologic therapy. 2 A 2002 to 2009 survey found that MET use was infrequent before 2007, and from 2007 to 2009, it was prescribed in 14% of emergency department urolithiasis visits. 3 This article compiles and briefly reviews the studies, including metaanalyses, that examined the efficacy and safety of alphablockers as MET in the treatment of kidney stones. Alpha-blockers, or alpha-1 antagonists, act by preventing adrenergic agonists, like norepinephrine, from stimulating the smooth muscles that regulate the diameter of smaller veins and arteries and the urinary system. This increased dilation of the urinary system is thought to allow kidney stones to pass more quickly out of the body. 4 Alpha-blockers are approved for benign prostatic hyperplasia and hypertension. They have an off-label use in the management of kidney stones. Agents selective to the prostate have less systemic adverse effects than nonselective agents. A summary of available alpha-blockers can be found in Table 1 .
The 2014 American Urological Association (AUA) guidelines for management of urolithiasis focus on stone prevention with diet and medications. Recurrent calcium stones can be prevented with thiazide diuretics or potassium citrate, while urate-containing stones can be prevented with allopurinol. Dietary recommendations include drinking plenty of water, limiting sodium intake, and reducing consumption of animal protein. 5 The 2016 European Association of Urology (EAU) guidelines on conservative management of urolithiasis recommend alpha-blockers with nonsteroidal anti-inflammatory drugs for recurrent renal colic, for facilitating passage of debris from lithotripsy, and as MET (without lithotripsy) for uncomplicated stones. The EAU makes no recommendation on choice of alpha-blocker. Though many stones <6 mm in diameter pass spontaneously, patients who choose observation or MET should return for follow-up within 2 weeks to assess for hydronephrosis and stone position. 6 This approach is also recommended by the 2016 AUA guidelines for surgical management of stones, which recommend offering MET with alpha-blocker therapy to patients with distal ureteral stones ≤10 mm (Grade B recommendation). They performed a meta-analysis of 24 studies and found a 73% versus 54% stone-free rate for patients with <10 mm distal ureteral stones treated with MET versus placebo or no treatment. They recommend a more definitive stone treatment (eg, SWL) if MET is not successful in 4 to 6 weeks. These guidelines do not recommend a specific alpha-blocker or dose, but they acknowledge that their recommendation was heavily influenced by studies using tamsulosin 0.4 mg daily. They also recommend alpha-blockers to help relieve stent discomfort and to facilitate passage of stone fragments following SWL. 
Data Sources
A PubMed search was performed on November 15, 2017, using the search terms alpha-blocker, alfuzosin, silodosin, or tamsulosin AND kidney or ureteral stones. Additional studies were found through references of primary and tertiary literature. Inclusion criteria included English language, randomized controlled trials (RCTs; not included in meta-analyses), and meta-analyses evaluating US available alpha-blockers as MET with or without lithotripsy in adults with renal or ureteral stones, and no date limits.
Summary of Studies
Fourteen studies, including 6 meta-analyses, 7 RCTs (not included in meta-analyses), and 1 case-control study (not included in meta-analyses) examined the efficacy and safety of alpha-blockers as MET for renal or ureteral stones. Agents studied include alfuzosin, doxazosin, naftopidil, silodosin, tamsulosin, terazosin, and urapidil. Naftopidil, an uroselective alpha-blocker, and urapidil, a nonselective alpha-blocker, are not available in the United States. Studies had similar inclusion criteria, including age greater than 18 years and presence of a single symptomatic and trackable kidney stone located in the ureter, renal pelvis, or renal calyx. Exclusion criteria included presence of more than one stone, urinary tract infection, and renal colic lasting more than a day. Study durations varied between 2 weeks and 6 months. The most commonly studied primary endpoint was clearance or expulsion rate, which was successful passing of the stone. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] A summary of studies can be found in Table 2 .
Four meta-analyses and 2 other (RCTs) evaluated alphablockers compared with placebo or other pharmacologic therapy without lithotripsy for management of ureteral stones ≤10 mm in diameter. [8] [9] [10] [11] [12] [13] In a Japanese study, there was no difference in clearance rate between tamsulosin 0.2 mg daily and conservative treatment. The authors acknowledged that 0.4 mg is the accepted tamsulosin MET dose, but only the 0.2 mg for benign prostatic hyperplasia is covered by the Japanese health insurance system. 8 A Chinese study found both tamsulosin 0.4 mg (82.2%) daily and naftopidil (72.1%) to be more effective than placebo (30.2%) at clearing stones. 9 There are published meta-analyses for each of the selective alpha-blockers (alfuzosin, silodosin, tamsulosin) and one that evaluated all alpha-blockers (selective and nonselective). [10] [11] [12] [13] The tamsulosin meta-analysis included more than 2700 patients from 29 trials and found a 33% improvement in clearance rate with tamsulosin (0.2 mg and 0.4 mg daily) compared with control. Tamsulosin cleared stones more than calcium channel blockers (6 studies). Tamsulosin 0.4 mg daily was shown to be equally effective to tamsulosin 0.2 mg daily (small study). There was no difference in expulsion rate between tamsulosin and lithotripsy for stones 4 to 8 mm in diameter, but >8 mm stones were cleared faster with lithotripsy compared with tamsulosin (1 study). 10 The alfuzosin meta-analysis included more than 700 patients from 7 trials and found an 85% improvement in clearance rate with alfuzosin 10 mg daily compared with control. 11 The silodosin meta-analysis included more than 1000 patients from 7 trials and found a 69% improvement with silodosin 8 mg daily in clearance rate compared with control. 12 The alpha-blocker meta-analysis included almost 6000 patients from 55 trials and found a 49% improvement in clearance rate with alpha-blockers over control. The results were not stratified by drug or dose. 13 Five RCTs, 1 case-control study, and 2 meta-analyses (tamsulosin, alpha-blockers) examined alpha-blockers as adjunctive therapy post-lithotripsy for renal or ureteral stones. [14] [15] [16] [17] [18] [19] [20] [21] For the RCTs, stone sizes were 4 to 20 mm in diameter. Tamsulosin 0.4 mg daily was studied in 4 of the 5 RCTs. Its clearance rate at 4 weeks was 73% to 86% versus 55% to 69%, at 8 weeks was 95% versus 57%, and at 12 weeks was 78% to 91% versus 46% to 74% compared with control. The results were significant for all but one of the 12-week trials. [15] [16] [17] [18] 21 Three RCTs found tamsulosin to be beneficial in reducing renal colic. 14, 16, 21 One tamsulosin RCT stratified for stone size and found it to be more effective for larger stones (11-20 mm) compared with smaller stones (≤10 mm). 17 The clearance rate for alfuzosin 10 mg daily compared with control in one RCT was 76.7% versus 46.7% for renal stones 11 to 15 mm. There was no difference for stones 5 to 10 mm. 18 The tamsulosin meta-analysis included more than 1300 patients from 15 trials and found a 24% improvement in clearance rate with tamsulosin 0.4 mg daily compared with control for upper urinary tract stones. The results were not stratified by stone size. It also found more benefit with 0.4 mg compared with 0.2 mg daily. 14 The alpha-blocker meta-analysis included almost 2900 patients from 26 studies and found significant improvement in stone-free rate (odds ratio 2.77) with both alpha-blockers and nifedipine compared with control for upper urinary tract stones. Results were not affected by stone size or location. 20 In a case-control study, Taiwanese patients that used alpha-blockers post-lithotripsy were monitored for up to 180 days, and it was found that the longer the patients received alpha-blockers the less likely they were to have a recurrence. The recurrence rate for the first (days 1-45) and fourth (days 135-180) quartiles were 45.64 and 18.52, respectively, per 1000-person years. 19 Reports of adverse events in the studies were rare, and no serious adverse events were associated with alphablocker use. Reported adverse effects included dizziness, hypotension, headache, and ejaculatory dysfunction. There was no difference in adverse effects based on alpha-blocker uroselectivity. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Dilation of the vasculature by alphablockers results in a moderate lowering of blood pressure, averaging −8 mm Hg systolic and −5 mm Hg diastolic, according to a Cochrane review. 22 This decrease in blood pressure is responsible for dizziness (3% to 19%) and headache (0% to 21%), which are the most common adverse events associated with alpha-blockers. Orthostatic hypotension has also been reported in patients initiating alphablocker therapy (0% to 19%) but occurs less frequently with chronic use (0% to 4%). 23 Overall, studies of alpha-blockers as MET for kidney stones were small with variable study design and quality. Because of the different study designs (randomized but open label or blinded), drug/dose/duration, primary endpoint, adverse effect reporting, and follow-up periods for the studies included in the meta-analyses, heterogeneity was present and expected and can lead to potential bias for the results. Despite that, studies found benefit with alpha-blockers as MET. A large clinical trial comparing the selective alpha-blockers (alfuzosin, silodosin, and tamsulosin) in terms of stone clearance and time to stone clearance based on stone size and location and safety is needed.
Conclusion
Current studies support the use of alpha-blockers as MET without lithotripsy for facilitating passage and time to passage of symptomatic ureteral stones <10 mm in diameter. 
